This application is for the Gynecologic Oncology Group (GOG) CCOP Research Base. The GOG is a non-profit organization with the purpose of promoting excellence in the quality and integrigy of clinical and basic scientific research in the field of gynecologic malignancies. The GOG is committed to maintaining the highest standards in clinical trials development, execution, analysis, and distribution of results. Continuous evaluation of our processess is utilized in order to constantly improve the quality of patient care. The GOG is the premier clinical trial group in the treatment of gynecologic cancers and has developed an active cancer and prevention control program. This is a multi-modality clinical trials group consisting of oncologists, basic scienctist and many other health care disciplines. The full members are primarily academic centers and major health care facilities. The affiliate network is primarily community based institutions working under the supervision of a full member institution. In addition, the GOG serves as a research base for twenty-nine Community Clinical Oncology Programs (CCOP's) who provide national clinical trials in many areas that world not normally have access to national clinical trials. The CCOPs provide valuable input to cancer prevention and treatment trials. The Group enhances this input by design and activiation of Phase I, II and III trials relation to the prevention and treatment of gynecologic malignancies.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA101165-08
Application #
8138509
Study Section
Special Emphasis Panel (ZCA1-SRRB-3 (J1))
Program Officer
Kelaghan, Joseph
Project Start
2003-08-01
Project End
2012-05-31
Budget Start
2011-06-01
Budget End
2012-05-31
Support Year
8
Fiscal Year
2011
Total Cost
$5,799,948
Indirect Cost
Name
Gynecologic Oncology Group
Department
Type
DUNS #
136664096
City
Crofton
State
MD
Country
United States
Zip Code
21114
Oliver, Kate E; Brady, William E; Birrer, Michael et al. (2017) An evaluation of progression free survival and overall survival of ovarian cancer patients with clear cell carcinoma versus serous carcinoma treated with platinum therapy: An NRG Oncology/Gynecologic Oncology Group experience. Gynecol Oncol 147:243-249
Tewari, Krishnansu S; Sill, Michael W; Penson, Richard T et al. (2017) Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240). Lancet 390:1654-1663
Skates, Steven J; Greene, Mark H; Buys, Saundra S et al. (2017) Early Detection of Ovarian Cancer using the Risk of Ovarian Cancer Algorithm with Frequent CA125 Testing in Women at Increased Familial Risk - Combined Results from Two Screening Trials. Clin Cancer Res 23:3628-3637
Mai, Phuong L; Piedmonte, Marion; Han, Paul K et al. (2017) Factors associated with deciding between risk-reducing salpingo-oophorectomy and ovarian cancer screening among high-risk women enrolled in GOG-0199: An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol 145:122-129
Lawrenson, Kate (see original citation for additional authors) (2016) Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus. Nat Commun 7:12675
Ovarian Cancer Association Consortium, Breast Cancer Association Consortium, and Consortium of Modifiers of BRCA1 and BRCA2 (see original citation for additional authors) (2016) No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. Gynecol Oncol 141:386-401
Chan, John K; Brady, Mark F; Penson, Richard T et al. (2016) Weekly vs. Every-3-Week Paclitaxel and Carboplatin for Ovarian Cancer. N Engl J Med 374:738-48
Zeng, Chenjie (see original citation for additional authors) (2016) Identification of independent association signals and putative functional variants for breast cancer risk through fine-scale mapping of the 12p11 locus. Breast Cancer Res 18:64
Coleman, Robert L; Sill, Michael W; Thaker, Premal H et al. (2015) A phase II evaluation of selumetinib (AZD6244, ARRY-142886), a selective MEK-1/2 inhibitor in the treatment of recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol 138:30-5
Blanco, Ignacio; Kuchenbaecker, Karoline; Cuadras, Daniel et al. (2015) Assessing associations between the AURKA-HMMR-TPX2-TUBG1 functional module and breast cancer risk in BRCA1/2 mutation carriers. PLoS One 10:e0120020

Showing the most recent 10 out of 36 publications